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Abstract Receptor-mediated phospholipase D activation in 
human embryonic kidney (HEK) cells stably expressing the m3 
muscarinic acetylcholine receptor (mAChR) apparently involves 
the small G protein RhoA. Here, activation of RhoA was 
examined by measuring cytosol-membrane translocation, which 
is a sign of RhoA activation. RhoA translocation was induced by 
guanosine 5'-0-(3-thio)triphosphate in digitonin-permeabilized 
HEK cells, and in intact cells by the agonist-activated mAChR 
and by direct activation of heterotrimeric G proteins. RhoA 
translocation was also induced by the phosphotyrosine phospha-
tase inhibitor pervanadate, while the tyrosine kinase inhibitors 
tyrphostin 23 and genistein inhibited the mAChR-induced RhoA 
translocation. These data suggest that translocation and thus 
activation of RhoA by the G protein-coupled m3 mAChR in 
HEK cells apparently involves a tyrosine kinase-dependent 
reaction. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Rho family GTPases, a subgroup of the Ras superfamily of 
low molecular weight guanine nucleotide-binding proteins (G 
proteins), play essential roles in various cellular functions, 
predominantly in the organization of the actin cytoskeleton 
[1^4] and cell growth and transformation [5-9]. These 
GTPases serve as molecular switches which are inactive in 
the GDP-bound state and active in the GTP-bound state. 
Cycling between these states is controlled by several regula-
tory proteins, such as guanine nucleotide dissociation inhibi-
tors (GDIs), guanine nucleotide exchange factors and 
GTPase-activating proteins [1]. 
R h o A is one of the most abundant members of the Rho 
family and present in all tissues so far examined [1,10]. In 
unstimulated cells, R h o A is localized predominantly in the 
cytosol with usually only a small fraction associated with 
the plasma membrane [11-14]. The cytosolic location is appar-
ently due to binding of RhoA to R h o G D I , a protein which 
inhibits G D P dissociation as well as G T P hydrolysis [15-17]. 
The process of R h o A activation by G D P / G T P exchange is 
closely associated with the translocation of R h o A from the 
cytosol to the plasma membrane [1,14]. It is not clear, how-
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ever, whether translocation is a consequence of activation or 
whether translocation of R h o A to the plasma membrane is a 
prerequisite for interaction with its guanine nucleotide ex-
change factor(s) [18]. When Rho returns to the inactive, 
GDP-bound state, it is supposed to form a new complex 
with R h o G D I and regains its cytosolic localization. Thus, 
the activation-inactivation cycle of R h o A by G T P binding 
and hydrolysis is closely related to a cytosol-membrane trans-
location cycle. 
Previous studies with Rho-inactivating toxins demonstrated 
that Rh o A is involved in receptor activation of phospholipase 
D (PLD) [19,20] and phospholipase C [21,22] in various cell 
types. The aim of the present study was to study receptor-
induced R h o A activation, by measuring translocation of 
R h o A from the cytosolic to the membrane fraction, in human 
embryonic kidney (HEK) cells, stably expressing the human 
m3 muscarinic acetylcholine receptor (mAChR). The data 
presented indicate that agonist activation of the m3 m A C h R 
induces R h o A translocation and that this G protein-coupled 
receptor action apparently involves a tyrosine kinase-depend-
ent process. 
2. Materials and methods 
2.1. Materials 
RhoA antibody was purchased from Santa Cruz (Heidelberg, Ger-
many). Genistein and tyrphostin 23 were from Biomol (Hamburg, 
Germany) and nitrocellulose membranes from Microdevices (Alaba-
ma, India). All other materials were from previously described sources 
[19,23]. 
2.2. Cell culture 
Culture conditions of HEK cells stably expressing the human m3 
mAChR were as reported in detail before [23]. For experiments, cells 
subcultured in Dulbecco's modified Eagle's medium/F-12 medium 
were grown to near confluence (175 cm2 culture flasks). 
2.3. Translocation assays 
For measurement of RhoA translocation, culture medium was dis-
charged, and cells were carefully rinsed with phosphate-buffered saline 
(PBS), containing 137 mM NaCl, 2.7 mM KC1, 0.5 mM MgCl2, 0.9 
mM CaCl2, 6.5 mM Na 2HP0 4 and 1.5 mM KH 2P0 4 , pH 7.2, before 
detachment from the culture flasks. Cells were washed once in PBS 
and then resuspended in PBS at a density of about 5 X 107 cells/ml. In 
some experiments, cells were washed and resuspended in Mg2+- and 
Ca2+-free PBS (composition see above, except that Mg2~ and Ca2~ 
were not included). 50 ul of the cell suspension (2X106 cells) was 
incubated at 37°C for varying periods of time with or without stimuli 
as indicated in the figure legends. Thereafter, 950 ul of permeabiliza-
tion buffer, containing 20 mM HEPES, pH 7.2, 135 mM KC1, 5 mM 
NaCO,,, 5.6 mM D-glucose, 2 mM ATP, 4 mM MgCl2, 5 mM EGTA, 
1.5 mM CaCl2 (corresponding to 40 nM free Ca
2+) and 8 uM dig-
itonin, was added, followed by a further incubation period of 10-60 
min. Routinely and if not indicated otherwise, permeabilization was 
performed for 10 min. Afterwards, cells were pelleted by centrifuga-
tion at 15 000Xg for 1 min, and RhoA contents of supernatant and 
pellet fractions were analyzed as follows: a 300 (il aliquot of the 
supernatant (corresponding to about 60 ug protein) was precipitated 
with 6% (mass/vol., final concentration) trichloroacetic acid and 
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0.0125% (mass/vol., final concentration) deoxycholate, and precipi-
tated proteins were subjected to SDS/PAGE on gels containing 15% 
(mass/vol.) acrylamide. The cell pellet, representing either a crude 
membrane fraction or intact cells, was resuspended in 200 ul Laemmli 
buffer, incubated at 95°C for 10 min, and an aliquot (20 ul, corre-
sponding to about 60 ug protein) was subjected to SDS/PAGE. 
2.4. Immunoblot analysis 
Following SDS/PAGE, proteins were transferred from polyacryl-
amide gels onto nitrocellulose filters and analyzed by standard proce-
dures. The blots were blocked for 2 h with 5% (mass/vol.) bovine 
serum albumin and incubated with the polyclonal rabbit anti-RhoA 
antibody (dilution 1:1000). Afterwards, the blots were incubated with 
a goat anti-rabbit IgG-peroxidase conjugate (1:4000 dilution, Sigma), 
before bound antibodies were detected by enhanced chemilumines-
cence (Amersham). The staining of immunoblots was quantified by 
densitometry (QuantiScan program, Biosoft). 
2.5. Data presentation 
The results shown are characteristic of at least three similar experi-
ments. 
3. Results 
Treatment of m3 mAChR-expressing HEK cells during dig-
itonin permeabilization with the stable GTP analog guanosine 
5'-0-(3-thio)triphosphate (GTPyS), induced translocation of 
RhoA from the cytosolic to the membrane fraction (Fig. 1). 
Permeabilization of HEK cells with digitonin markedly re-
duced RhoA content of the crude membrane fraction com-
pared to non-permeabilized cells, and this effect was almost 
complete when permeabilization was for 60 min (Fig. 1A). 
However, when GTPyS (100 \xM) was present during perme-
abilization, loss of RhoA during permeabilization was fully 
Fig. 2. mAChR-stimulated RhoA translocation. A: m3 mAChR-ex-
pressing HEK cells were treated with or without 100 uM carbachol 
for 3 min prior to permeabilization with digitonin (10 min) in the 
presence of the indicated concentrations of GTPyS. B: HEK cells 
were treated with or without 100 uM carbachol in the presence or 
absence of 100 u,M atropine for 3 min prior to permeabilization by 
digitonin in the presence of 1 uM or 10 uM GTPyS. C: HEK cells 
were treated with the indicated concentrations of carbachol for 
3 min prior to digitonin permeabilization in the presence of 1 uM 
GTPyS. The RhoA content of supernatant fractions was determined. 
Lanes 1 in A-C: non-permeabilized cells. 
Fig. 1. GTPyS-stimulated translocation of RhoA from the cytosol 
to the membrane fraction. A: HEK cells were permeabilized with 
digitonin in the absence and presence of 100 uM GTPyS for 30 min 
(lanes 1-3) or 60 min (lanes 4-6), and after centrifugation the pellet 
fraction was analyzed for RhoA content as described in Section 2. 
Lanes 1 and 4: non-permeabilized cells. Molecular weight markers 
are indicated on the right. B: Digitonin permeabilization of HEK 
cells was performed for 30 min at the indicated concentrations of 
GTPyS. Subsequently, the supernatant was analyzed for RhoA con-
tent. Lane 1 : non-permeabilized cells. 
prevented. RhoA contents of non-permeabilized cells and of 
the crude membrane fraction of HEK cells permeabilized in 
the presence of GTPyS were virtually identical, strongly sug-
gesting that the stable GTP analog induced translocation of 
cytosolic RhoA to the membrane fraction. This translocation 
of RhoA was reflected in a GTPyS-induced decrease in cyto-
solic RhoA, released during permeabilization of HEK cells 
with digitonin (Fig. IB). Under the experimental conditions 
used, half-maximal and maximal effects on RhoA release were 
achieved with about 3 u,M and 100 uM GTPyS, respectively, 
as determined by densitometric quantification. Thus, RhoA 
translocation could be detected both as increase in mem-
brane-bound RhoA and decrease in cytosolic RhoA. In order 
to minimize RhoA degradation possibly occurring during pro-
longed digitonin permeabilization required for full release of 
RhoA, cytosolic and crude membrane fractions were routinely 
prepared after 10 min permeabilization of HEK cells with 
digitonin. Under this condition, about 60% of cellular RhoA 
in unstimulated HEK cells was pelleted with the crude mem-
brane fraction. Therefore, in the following translocation of 
RhoA is illustrated as decrease in release of cytosolic RhoA. 
Next, we studied whether agonist activation of the stably 
expressed m3 mAChR can induce RhoA translocation. For 
this, intact HEK cells were first stimulated for 3 min with and 
without carbachol, followed by digitonin permeabilization in 
the presence of GTPyS. When GTPyS was not added to the 
permeabilization buffer, a receptor-stimulated RhoA translo-
cation was not observed under standard assay conditions (but 
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Fig. 3. Time course of carbachol-induced RhoA translocation; influ-
ence of AlF^". m3 mAChR-expressing HEK cells washed and resus-
pended in Mg2+- and Ca2+-free PBS were treated with or without 
100 uM carbachol or A1F~ (10 mM NaF plus 10 uM A1C13) for 
3 min (lanes 1-3), 10 min (lanes 4-6) or 30 min (lanes 7-12) as indi-
cated prior to permeabilization by digitonin (10 min). The superna-
tant fractions were analyzed for RhoA content. Lanes 1, 4, 7 and 
10: non-permeabilized cells. 
tion of RhoA release was almost complete in cells pretreated 
with 4 mM pervanadate. On the other hand, the tyrosine 
kinase inhibitors, tyrphostin 23 and genistein, effectively in-
hibited carbachol-induced RhoA translocation. Preincubation 
of HEK cells with 100 uM tyrphostin 23 for 30 min before 
stimulation with carbachol (100 uM, 3 min) nearly completely 
prevented the agonist-induced potentiation of inhibition of 
RhoA release by GTPyS (1 uM) (Fig. 4B, compare lanes 3 
and 4 with lanes 7 and 8). Similarly, preincubation of HEK 
cells with genistein (100 uM, 30 min) also markedly reduced 
the inhibitory agonist effect on RhoA release (Fig. 4B, com-
pare lanes 3 and 4 with lanes 11 and 12). 
4. Discussion 
see below). However, pre-stimulation of HEK cells with car-
bachol markedly potentiated GTPyS-induced RhoA translo-
cation. As shown in Fig. 2A, stimulation of HEK cells with 
100 uM carbachol, followed by digitonin permeabilization in 
the presence of 0.1-10 uM GTPyS, strongly increased the 
inhibitory effect of GTPyS on RhoA release compared to cells 
treated with GTPYS alone. This potentiating effect of carba-
chol on GTPyS-induced inhibition of RhoA release was fully 
prevented when carbachol (100 u\M) pretreatment of HEK 
cells was performed in the presence of the muscarinic receptor 
antagonist atropine (100 uM) (Fig. 2B). The potentiating ef-
fect of carbachol on inhibition of RhoA release was concen-
tration-dependent. In the presence of 1 uM GTPyS, which by 
itself had only a small effect on RhoA release, half-maximal 
potentiation of inhibition of RhoA release was observed at 
about 20 uM carbachol (Fig. 2C). 
mAChR-stimulated RhoA translocation in HEK cells could 
also be demonstrated, even without addition of GTPyS to the 
permeabilization buffer, when the cells were incubated in 
Mg2+- and Ca2+-free PBS. As illustrated in Fig. 3, under 
this condition, treatment of HEK cells with carbachol induced 
a biphasic RhoA translocation. In cells pretreated for 3 min 
with carbachol (100 uM), release of RhoA into the superna-
tant was almost fully prevented. Upon prolonged treatment of 
HEK cells, the inhibitory effect of carbachol was reduced and 
fully lost in cells treated for 30 min with carbachol. These 
data, additionally, demonstrate that receptor-induced inhibi-
tion of RhoA release is not due to RhoA degradation. As 
signal transduction of the mAChR is mediated by heterotri-
meric G proteins, we examined whether direct activation of 
these G proteins can also induce RhoA translocation. Prein-
cubation of HEK cells with AlF^ (10 mM NaF plus 10 uM 
AICI3) prior to permeabilization strongly inhibited RhoA re-
lease (Fig. 3, lanes 10-12). Similar to the mAChR agonist 
action, AlF^ -regulated RhoA translocation was only observed 
when cells were incubated in Mg2+- and Ca2+-free PBS (data 
not shown). In contrast to carbachol, however, the inhibitory 
effect of AlF^ on RhoA release was retained even after 30 min 
stimulation of HEK cells with this direct activator of hetero-
trimeric G proteins. 
Since evidence has been provided that a tyrosine kinase is 
involved in receptor signaling to RhoA [24], we studied the 
effects of tyrosine kinase and phosphotyrosine phosphatase 
inhibitors on RhoA translocation in HEK cells. As shown 
in Fig. 4A, treatment of HEK cells for 30 min with the phos-
photyrosine phosphatase inhibitor pervanadate [25,26] caused 
a concentration-dependent decrease in RhoA release. Inhibi-
Although there is ample evidence that Rho proteins are 
crucial for the regulation of the actin cytoskeleton organiza-
tion and also have critical functions in the control of cell 
proliferation, until now, most information on the role of 
Rho in receptor signaling pathways has been obtained by 
rather indirect methods, using either constitutively active 
and dominant-negative Rho protein mutants or Rho-inacti-
vating toxins. Since GDP/GTP exchange-dependent activation 
of RhoA is coupled with a translocation of this G protein 
from the cytosol to the plasma membrane, we examined in 
the present study the subcellular redistribution of RhoA in 
response to various stimuli to measure RhoA activation. 
Translocation of RhoA was quantified in HEK cells stably 
expressing the human m3 mAChR, in which previous studies, 
using the Rho-inactivating toxins, toxin B and C3 exoenzyme, 
demonstrated that Rho proteins, most likely RhoA, are in-
volved in receptor signaling to PLD and phospholipase C 
[19,21]. 
Similar as reported in other cell types [18], incubation of 
permeabilized HEK cells with the stable GTP analog GTPyS 
Fig. 4. Regulation of RhoA translocation by tyrosine phosphoryla-
tion. A: HEK cells were preincubated with the indicated concentra-
tions of pervanadate for 30 min prior to permeabilization by digito-
nin (10 min). B: HEK cells preincubated for 30 min with or 
without 100 U.M tyrphostin 23 or genistein were treated with or 
without 100 uM carbachol for 3 min, followed by digitonin permea-
bilization (10 min) in the presence or absence of 1 uM GTPyS as in-
dicated. Lanes 1, 5 and 9: non-permeabilized cells. RhoA content 
of supernatant fractions is demonstrated. 
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led to a concentration-dependent translocation of cytosolic 
R h o A to the particulate fraction. The translocation could be 
demonstrated both as a GTPyS-induced decrease in release of 
cytosolic R h o A and as an increase in R h o A content of the 
particulate fraction. As studies in other cell types demon-
strated that R h o A is predominantly localized in the cytosol 
and/or at the plasma membrane [11-14], the translocation of 
R h o A to the particulate fraction of H E K cells probably re-
flects association of R h o A with the plasma membrane. 
Translocation of R h o A was not only induced by the stable 
G T P analog, most likely by direct binding to RhoA. Incuba-
tion of intact HEK cells with the m A C h R agonist, carbachol, 
and AlF^", a direct activator of heterotrimeric G proteins, also 
induced R h o A translocation. Complete inhibition of carba-
chol-stimulated translocation by concomitant incubation 
with atropine proves receptor specificity. Interestingly, repro-
ducible effects of both the receptor agonist alone and non-
selective activation of heterotrimeric G proteins by AlF^ on 
R h o A translocation could only be demonstrated when the 
cells were incubated under M g 2 + - and Ca2 +-free conditions. 
This may be explained by moderate lowering of cytosolic 
M g 2 + concentrations leading to facilitated G D P / G T P ex-
change, as reported for Rab5 proteins [27]. 
When cells prestimulated with carbachol were permea-
bilized in the presence of submaximal concentrations of 
GTPyS, there was a concentration-dependent, receptor ago-
nist-induced potentiation of R h o A translocation, suggesting 
that m A C h R activation facilitates GTPyS binding to RhoA. 
This finding contrasts with the lack of agonist effect on PLD 
activity measured in permeabilized H E K cells in the presence 
of GTPyS [23,28]. One possible explanation might be that for 
receptor-mediated and RhoA-dependent P L D stimulation ad-
ditional components are required which cannot be assembled 
in permeabilized cells. mAChR-induced translocation of 
RhoA was transient, with maximal effects being achieved 
within 3 min, and completely abolished upon prolonged ago-
nist activation. A similar transient agonist (lysophosphatidic 
acid)-induced R h o A translocation has been reported in ra t i 
fibroblasts [20]. Interestingly, mAChR-induced P L D stimula-
tion in H E K cells exhibits similar kinetics. Maximal P L D 
stimulation is rapidly reached and is then fully desensitized 
upon prolonged agonist treatment [28]. 
Tyrosine kinase inhibitors have been reported to inhibit 
mAChR-induced PLD stimulation in H E K cells [23] as well 
as lysophosphatidic acid-induced and RhoA-mediated forma-
tion of focal adhesions and actin stress fibers in Swiss 3T3 
fibroblasts [24]. These findings prompted us to investigate the 
role of tyrosine phosphorylation in translocation of R h o A in 
H E K cells. The phosphotyrosine phosphatase inhibitor perva-
nadate [25,26], which induced strong tyrosine phosphorylation 
of various proteins in H E K cells [23] (data not shown), effec-
tively induced R h o A translocation, suggesting that a tyrosine 
kinase/phosphotyrosine phosphatase cycle is maintained in a 
basal activity state in H E K cells similar as reported for other 
cells [3,25,26]. In support of the data obtained with pervana-
date, suggesting that a tyrosine phosphorylation-dependent 
event is involved in R h o A activation, we observed that the 
tyrosine kinase inhibitors, tyrphostin 23 and genistein, effec-
tively inhibited mAChR-st imulated R h o A translocation. 
These data strongly suggest that an as yet unidentified tyro-
sine kinase(s) participates in translocation and thus activation 
of R h o A by the G protein-coupled m3 m A C h R in H E K cells. 
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